Cargando…
Clinical evaluation of BCL-2/X(L) levels pre- and post- HER2-targeted therapy
Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gene expression within tumor biopsies, collected befo...
Autores principales: | Zoeller, Jason J., Press, Michael F., Selfors, Laura M., Dering, Judy, Slamon, Dennis J., Hurvitz, Sara A., Brugge, Joan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099090/ https://www.ncbi.nlm.nih.gov/pubmed/33951110 http://dx.doi.org/10.1371/journal.pone.0251163 |
Ejemplares similares
-
Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
por: Zoeller, Jason J., et al.
Publicado: (2017) -
Erratum: Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo
por: Zoeller, Jason J., et al.
Publicado: (2017) -
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
por: Hurvitz, Sara A., et al.
Publicado: (2020) -
HER-2 overexpression differentially alters transforming growth factor-β responses in luminal versus mesenchymal human breast cancer cells
por: Wilson, Cindy A, et al.
Publicado: (2005) -
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
por: de Haas, Sanne L., et al.
Publicado: (2023)